WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ:ACUS) today issued the following letter to shareholders:
Dear Fellow Shareholders:
As we move into 2008, I want to provide Acusphere shareholders with a review of our progress in 2007 and our goals for 2008. We remain focused on our overall objective, ensuring that the New Drug Application (NDA) for our lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) for Injectable Suspension, is filed with the U.S. Food & Drug Administration (FDA) early this year. The key events of 2007, including the second of our Phase 3 trial results, our presentations at major medical conferences and the senior executives we added, combine to bolster our confidence in the strength of that application and the benefits that Imagify can provide.
